Dialysis vascular access intervention — the angioplasty, DCB, and stenting procedures for arteriovenous fistula and graft stenosis maintenance in end-stage renal disease patients — creates a specialized and high-volume peripheral vascular intervention market, with the Peripheral Angioplasty Market reflecting AV access as a commercially important peripheral intervention segment.

AV access failure burden — the approximately five hundred thousand US hemodialysis patients with AV fistulas and grafts requiring approximately six hundred thousand annual dialysis access interventions to maintain adequate flow for life-sustaining dialysis — creates the high-volume recurring intervention market. The average dialysis access requiring one to two interventions annually from the high neointimal hyperplasia rate creating the predictable commercial demand.

IN.PACT AV DCB (Medtronic) — the paclitaxel DCB with specifically enrolled AV access DCB clinical program — represents the first dedicated dialysis access DCB achieving FDA clearance based on the IN.PACT AV IDK trial. The IN.PACT AV's two-fold reduction in target lesion primary patency failure versus standard PTA creating the clinical evidence for DCB adoption in AV access.

Sirolimus DCB for AV access — the MagicTouch AV (Concept Medical) and Selution SLR AV showing early evidence of sirolimus DCB efficacy in the AV access indication — represent the next-generation DCB competition for the dialysis access market. The MATILDA and SALUTEM trials evaluating sirolimus DCB in AV access creating the emerging competitive evidence.

Do you think DCBs will become the standard of care for all AV access stenosis interventions, displacing plain balloon angioplasty as the first-line dialysis access treatment?

FAQ

What interventions are performed for dialysis AV access dysfunction? AV access interventions: balloon angioplasty (POBA): mainstay of treatment; stenosis identified by decreased flow, elevated pressures, or clinical examination; plain high-pressure balloon angioplasty; primary patency limited (fifty percent at six months from neointimal hyperplasia); DCB: IN.PACT AV FDA cleared; paclitaxel-coated balloon; INPACT AV IDK trial showing superior patency vs POBA; Stenting: bail-out for significant dissection or recoil; covered stents (Viabahn) for aneurysmal degeneration; Surgical revision: outflow anastomosis revision, jump graft; combined catheter-based intervention and surgical salvage algorithm based on lesion type.

What is the INPACT AV IDK trial and what did it show? IN.PACT AV IDK trial: randomized controlled trial; IN.PACT AV DCB versus standard PTA for AV fistula and graft stenosis; primary endpoint: target lesion primary patency at six months; results: DCB sixty-two percent versus PTA thirty-eight percent (p<0.001); secondary endpoints: secondary patency, number of repeat interventions all favored DCB; follow-up through twenty-four months showed sustained benefit; FDA approval 2020 for AV access; commercial uptake growing but requires procedural training and extra cost per intervention (~$1,000-1,500 premium vs POBA); AV access DCB growing from clinical evidence but not yet universal standard.

#PeripheralAngioplasty #DialysisAccess #AVfistula #DCBaccess #INPACTav #HemodialysisAccess